Study of KN026 in Combination With Docetaxel as Neoadjuvant Therapy in HER2-positive Breast Cancer
Status:
Not yet recruiting
Trial end date:
2022-12-15
Target enrollment:
Participant gender:
Summary
This is an open-lable, multicenter, and single arm phase II trial to evaluate treatment with
KN026 plus docetaxel as neoadjuvant therapy in patients with early-stage (T1c or 2, N1, M0;
T2 or 3, N0, M0) or locally advanced (T1c or 2 or 3, N2, M0; T3N1M0; T1c or 2 or 3, N3a or
3b, M0) HER2-positive breast cancer. The subjects will receive KN026 30 mg/kg IV + Docetaxel
75/m2 every 3 weeks for four cycles prior to surgery.